Health
Pancreatitis drug blocks SARS-CoV-2 activators in the upper respiratory tract – News-Medical.Net
Pancreatitis drug Camostat inhibits new SARS-CoV-2 activators identified in the upper respiratory tract.
There are no therapeutics available that have been developed…
Pancreatitis drug Camostat inhibits new SARS-CoV-2 activators identified in the upper respiratory tract.
There are no therapeutics available that have been developed for COVID-19 treatment. Repurposing already available medication for COVID-19 therapy is an attractive option to shorten the road to treatment development.
The drug Camostat could be suitable. Camostat exerts antiviral activity by blocking the protease TMPRSS2, which is used by SARS-CoV-2 for entry into cells.
However, it was previously…
-
General16 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
Noosa News22 hours agoFuel tanker driver killed in horror head-on crash near Blackbutt identified as beloved father-of-two
-
Noosa News20 hours agoPalestine protesters forced into last-minute reroute
-
Noosa News20 hours agoSuspected arsonist escapes in car while on fire after botched tobacconist attack